Vitamin D3 and brain wave patterns in men with Parkinson's disease and low vitamin D
Effect of Vitamin D3 Supplementation on Brain Waves in Male Parkinson's Disease Patients With Hypovitaminosis D : A Quantitative Electroencephalogram Analysis
This will test whether taking a weekly high-dose vitamin D3 capsule for 8 weeks changes brain wave patterns in men with Parkinson's disease who have low vitamin D levels.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 51 Years to 70 Years |
| Sex | Male |
| Sponsor | Bangladesh Medical University Academic / other |
| Locations | 1 site (Dhaka, Shahbag) |
| Trial ID | NCT07096336 on ClinicalTrials.gov |
What this trial studies
This is a single-arm, pretest-posttest trial enrolling 15 men with Parkinson's disease, confirmed low serum 25(OH)D, and Hoehn and Yahr stage up to 3. Participants will take oral vitamin D3 50,000 IU once weekly for 8 weeks and return for repeat serum 25(OH)D measurement and quantitative EEG. qEEG recordings will be processed with FFT to derive absolute and relative power, peak and median power frequency, and spectral edge frequency across delta, theta, alpha and beta bands. Within-subject changes will be analyzed using paired t-tests or Wilcoxon signed-rank tests after normality testing in SPSS.
Who should consider this trial
Good fit: Men aged 51–70 with Parkinson's disease up to H&Y stage 3, BMI 18.5–24.9, on levodopa, and with serum 25(OH)D below 30 ng/mL who are not currently taking vitamin D supplements would be ideal candidates.
Not a fit: People with normal vitamin D levels, advanced Parkinson's beyond stage 3, those taking medications that alter EEG (e.g., sedatives, antipsychotics, antidepressants), or with the listed comorbid medical conditions are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If positive, the intervention may point to a simple, low-cost supplement that can modify abnormal brain electrical activity in vitamin D–deficient men with Parkinson's disease.
How similar studies have performed: Evidence linking vitamin D to Parkinson's outcomes is limited and mixed, and using qEEG to detect neural effects of vitamin D supplementation in PD is largely novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male Patients with PD up to stage 3 according to Hoehn and Yahr (H-Y) scale * Age: 51years to70 years * BMI: 18.5-24.9 kg/m2 * Hypovitaminosis D (Serum 25(OH)D level \<30 ng/ml) * Patients on Levodopa therapy Exclusion Criteria: * Already taking vitamin D3 supplements * Current use of medication/substances known to affect neuronal excitability or EEG patterns, such as - sedatives, antidepressant, antipsychotics, alcohol. * Patients who are currently suffering from following diseases * Neurological disorders (Migraine, epilepsy) * Cardiovascular disorders (Myocardial infarction, hypertension, cardiac arrhythmia, heart failure) * Respiratory disorders (Bronchial asthma, COPD) * Psychiatric illness (e.g., schizophrenia, major depression, bipolar disorder, severe dementia) * With biochemical evidence of- * Hypercalcemia * Renal insufficiency * Liver diseases * Endocrine disorders (uncontrolled diabetes mellitus, Hypothyroidism, Hyperthyroidism) * Active smoker
Where this trial is running
Dhaka, Shahbag
- Bangladesh medical university — Dhaka, Shahbag, Bangladesh (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.